ArticleCell reports. Medicine2023
Direct activation of KCC2 arrests benzodiazepine refractory status epilepticus and limits the subsequent neuronal injury in mice.
Open access · goldAbstract read
In one paragraph
Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 31 citations in OpenAlex.
- WNK-SPAK/OSR1 signaling pathway facilitates ictal activity via reduced neuronal chloride extrusion rate.bioRxiv : the preprint server for biology · 2026Article
- Solute carrier membrane transporters: emerging targets in CNS disorders.Nature reviews. Drug discovery · 2026Review
- Synaptic correlates of benzodiazepine tolerance.Molecular psychiatry · 2026Review
- GABACellular and molecular neurobiology · 2026Review
- Enhancing KCC2 function reduces interictal activity and prevents seizures in temporal lobe epilepsy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- KCC2 activation during postnatal development alleviates long-term deficits in CDKL5-deficient mice.Experimental & molecular medicine · 2026Article
- Article
- Status epilepticus: Updates on mechanisms and treatments.Epilepsia open · 2025Review
- The Impact of Small Molecule on the Astrocyte's Viability Derived From Epileptic Brain Tissues.Basic and clinical neuroscience · 2025Article
- An Evaluation of Cation-Chloride Cotransporters NKCC1 and KCC2 in Carbamazepine-Resistant Rats.International journal of molecular sciences · 2025Article
- KCC2 inhibition and neuronal hyperexcitability promote extrinsic apoptosis dependent upon C1q.Frontiers in molecular neuroscience · 2025Article
- Timing of interventions to control neuronal chloride elevation in a model of neonatal seizures after hippocampal injury.Epilepsia · 2024Article
- New epilepsy therapies in development.Nature reviews. Drug discovery · 2024Review
- Article
- Heterogeneous subpopulations of GABAiScience · 2024Article
- The brain-specific kinase LMTK3 regulates neuronal excitability by decreasing KCC2-dependent neuronal CliScience · 2024Article
- Compound 350: A New Hope for Individuals with Drug-resistant Epilepsy.Annals of neurosciences · 2024Article
- The expression system influences stability, maturation efficiency, and oligomeric properties of the potassium-chloride co-transporter KCC2.Neurochemistry international · 2024Article
- Uncovering novel KCC2 regulatory motifs through a comprehensive transposon-based mutant library.Frontiers in molecular neuroscience · 2024Article
- Development of KCC2 therapeutics to treat neurological disorders.Frontiers in molecular neuroscience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 4 institutions in 2 countries.
Rebecca JarvisDiscovery, Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Shu Fun Josephine NgDepartment of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
Anna J NathansonDepartment of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
Ross A CardarelliDepartment of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
Krithika AbiramanDepartment of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
Fergus WadeDepartment of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
Aidan Evans-StrongDepartment of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
Marina P Fernandez-CampaDepartment of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
Tarek Z DeebDepartment of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
Joshua L SmalleyDepartment of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
Tanguy JamierDiscovery, Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Ian K GurrellDiscovery, Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Lisa McWilliamsDiscovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.
Aarti KawatkarDiscovery Biology, Discovery Sciences, R&D, AstraZeneca, Boston, MA, USA.
Leslie C ConwayDepartment of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
Qi WangDiscovery, Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA.
Roland W BurliDiscovery, Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Nicholas J BrandonDiscovery, Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA.
Iain P ChessellDiscovery, Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Aaron J GoldmanDepartment of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Jamie L MaguireDepartment of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
Stephen J MossDepartment of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA; Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1 6BT, UK. Electronic address: stephen.moss@tufts.edu.
Tufts University · USAstraZeneca (United Kingdom) · GBAstraZeneca (United States) · USHarvard University · US
Funding
Mechanisms that determine Glutamine synthetase activity in the brainR01NS081986 · NINDS · TUFTS UNIVERSITY BOSTON · PI MOSS, STEPHEN J · 2012 to 2022
$3.7MStudies on the structure of gamma-aminobutyric acid type A receptor subtypesR01MH118263 · NIMH · TUFTS UNIVERSITY BOSTON · PI MOSS, STEPHEN J · 2019 to 2023
$2.4MModulation of KCC2 activity and the postnatal development of synaptic inhibitionR01NS101888 · NINDS · TUFTS UNIVERSITY BOSTON · PI DEEB, TAREK ZIAD, MOSS, STEPHEN J · 2017 to 2021
$2.3MNovel actions of neurosteroids on GABA (A) receptor traffickingR01NS108378 · NINDS · TUFTS UNIVERSITY BOSTON · PI DAVIES, PAUL ANDREW, MOSS, STEPHEN J · 2018 to 2022
$2.0MDeficits in KCC2 activity and the pathophysiology of Status EpilepticusR01NS087662 · NINDS · TUFTS UNIVERSITY BOSTON · PI MOSS, STEPHEN J · 2014 to 2018
$2.0MMechanisms that determine the activity of glutamine synthetase in the brainR21NS103865 · NINDS · TUFTS UNIVERSITY BOSTON · PI MOSS, STEPHEN J · 2018 to 2019
$454kDetermining the effects of human KCC2 mutations on neuronal excitabilityR21NS111338 · NINDS · TUFTS UNIVERSITY BOSTON · PI DAVIES, PAUL ANDREW · 2019 to 2020
$454kNIMH NIH HHS R01 MH118263NINDS NIH HHS R01 NS081986NINDS NIH HHS R01 NS087662NINDS NIH HHS R01 NS101888NINDS NIH HHS R01 NS108378NINDS NIH HHS R21 NS103865NINDS NIH HHS R21 NS111338
Abstract
Hyperpolarizing GABA
Indexed as
Status EpilepticusSymportersAnimalsBenzodiazepinesgamma-Aminobutyric AcidMiceSeizuresBenzodiazepinesgamma-Aminobutyric AcidSymportersbenzodiazepineEEGepilepsyKCC2neuronal Cl(−) extrusionneuronal deathneuroprotectionrefractory status epilepticussynaptic inhibition
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.